1-7 of 7
Murray Yule
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell-Hewson, Guy Makin, Sarah E.R. Halford, Gary Acton, Philip Ross, Shamim Kazmi-Stokes, Victoria Lock, Ana Rodriguez, John F. Lyons, Alan V. Boddy, Melanie J. Griffin, Murray Yule, Darren Hargrave
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 267–273.
https://doi.org/10.1158/1078-0432.CCR-14-1592
Published: 14 January 2015
View article titled, A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
Open the PDF for A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

Geoffrey I. Shapiro, Eunice Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John Lyons, Daruka Mahadevan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (1): 87–97.
https://doi.org/10.1158/1078-0432.CCR-14-0979
Published: 05 January 2015
View article titled, First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Biomarker identification for AT9283 a multi-targeted kinase inhibitor with Aurora A and B activities from pre-clinical models to clinical trials.

John Lyons, Matt Squires, Murray Yule, Victoria Lock, Jayne Curry, Matthias Reule, Neil Thompson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): B15.
Published: 15 August 2014
View article titled, Biomarker identification for AT9283 a multi-targeted kinase inhibitor with Aurora A and B activities from pre-clinical models to clinical trials.
Journal Articles

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Denis C. Talbot, Joachim von Pawel, Emma Cattell, S. Murray Yule, Claire Johnston, Anthe S. Zandvliet, Alwin D.R. Huitema, Chris J. Norbury, Paul Ellis, Leon Bosquee, Martin Reck
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1816–1822.
https://doi.org/10.1158/1078-0432.CCR-06-0249
Published: 15 March 2007
View article titled, A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck: Modulation of Retinoblastoma Protein Phosphorylation by a Novel Chloroindolyl Sulfonamide Cell Cycle Inhibitor

Robert I. Haddad, Lisa J. Weinstein, Tad J. Wieczorek, Nandita Bhattacharya, Harry Raftopoulos, Martin W. Oster, Xinxin Zhang, Vaughan M. Latham, Jr., Rosemary Costello, Jarrod Faucher, Carolyn DeRosa, Murray Yule, Linda P. Miller, Massimo Loda, Marshall R. Posner, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4680–4687.
https://doi.org/10.1158/1078-0432.CCR-04-0229
Published: 21 July 2004
View article titled, A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck: <subtitle>Modulation of Retinoblastoma Protein Phosphorylation by a Novel Chloroindolyl Sulfonamide Cell Cycle Inhibitor</subtitle>
Open the PDF for A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck: <subtitle>Modulation of Retinoblastoma Protein Phosphorylation by a Novel Chloroindolyl Sulfonamide Cell Cycle Inhibitor</subtitle> in another window
Journal Articles

Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma

S. Murray Yule, Lisa Price, Alex D. McMahon, Andrew D. J. Pearson, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (2): 455–460.
https://doi.org/10.1158/1078-0432.CCR-0844-03
Published: 03 February 2004
View article titled, Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma
Open the PDF for Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma in another window
Journal Articles

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Christian Dittrich, Herlinde Dumez, Hilary Calvert, Axel Hanauske, Marije Faber, Jantien Wanders, Murray Yule, Miroslav Ravic, Pierre Fumoleau
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5195–5204.
Published: 12 November 2003
View article titled, Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors in another window